Bio-Rad Launches PTC Tempo 96 and PTC Tempo Deepwell Thermal Cyclers

Bio-Rad Launches PTC Tempo 96 and PTC Tempo Deepwell Thermal Cyclers

PTC Tempo 96 Thermal Cycler

HERCULES, Calif.—Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced the launch of its PTC Tempo 96 and PTC Tempo Deepwell Thermal Cyclers, designed to optimize PCR applications such as sequencing, cloning, and genotyping.

The PTC Tempo 96 and PTC Tempo Deepwell Thermal Cyclers are a new generation of conventional PCR thermal cyclers from Bio-Rad. The latest design is built with a refreshed, intuitive user interface and flexible connectivity features for streamlining protocol management. A motorized lid allows for automation compatibility and modern instrument control for workflows. The PTC Tempo Thermal Cycler is engineered to maintain superior thermal performance, delivering accurate results alongside the flexibility to expand and grow within the laboratory.

"The new line of PTC Tempo Thermal Cyclers delivers the same reliability and high-quality performance that Bio-Rad has been providing to customers for over 30 years," said Steven Blakely, Senior Director, Gene Expression, Bio-Rad. "With this engineering expertise, we have developed and manufactured robust and efficient thermal cyclers that scientists need and want."

These PCR instruments offer enhanced usability with features designed to support academic, commercial, and biopharma labs in conducting basic and translational research, process development, and quality control.

Please visit for more information about the PTC Tempo Thermal Cycler.

BIO-RAD is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With 70 years of focus on quality and customer service, our products advance the scientific discovery process and improve healthcare. Our customers are universities, research institutions, hospitals, biotechnology and pharmaceutical companies, as well as public health and commercial laboratories including food safety and environmental quality testing facilities. Based in Hercules, California, Bio-Rad has a global network of operations with approximately 8,300 employees worldwide and $2.8 billion in revenues in 2022. For more information, please visit

Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, supply chain risks, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Media Contacts:
Bio-Rad Laboratories, Inc.
Katrina Academia, Inbound Marketing Manager
+1 510-356-7909

Zyme Communications
Esmé Walters
+44 (0) 7737 543244